Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 0.52 |
| ▸ | PDE4A | P27815 | 8/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.52 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030016 | 0.91 | PDE4B (0.61) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1013024 | 0.88 | KMO (0.52) | PDE4BPDE4APDE4CPDE4DPARP15 | |
| SCHEMBL184260 | 0.87 | PDE4B (0.70) | PDE4BPDE4APDE4CPDE4DABCB11 | |
| SCHEMBL17050364 | 0.86 | PDE4B (0.46) | PDE4BPDE4APDE4CPDE4DPARP15 | |
| SCHEMBL15968595 | 0.86 | PDE4B (0.46) | PDE4BPDE4APDE4CPDE4DPARP15 | |
| SCHEMBL7362324 | 0.86 | PDE4B (0.58) | PDE4BPDE4APDE4CPDE4DPARP15 | |
| SCHEMBL28034346 | 0.85 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DPARP15 | |
| SCHEMBL1013056 | 0.84 | XDH (0.53) | PARP15PARP10PARP2 | |
| SCHEMBL12881162 | 0.84 | PARP15 (0.42) | PDE4BPDE4APDE4CPDE4DPARP15 | |
| SCHEMBL28033753 | 0.81 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202880-B2 | 3-hydroxy-6-phenylphenanthridines as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-7632844-B2 | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | NYCOMED GMBH (DE) | 2009-12-15 | — | — | US | disclosed |
| US-20090170892-A1 | 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors | NYCOMED GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20080319067-A1 | 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | NYCOMED GMBH | 2008-12-25 | — | — | US | disclosed |
| US-7423046-B2 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | NYCOMED GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7329676-B2 | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | NYCOMED GMBH (DE) | 2008-02-12 | — | — | US | disclosed |
| EP-1536798-B1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2007-02-07 | — | — | EP | disclosed |
| EP-1539164-B1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| US-20050239818-A1 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | ALANA PHARMA AG (DE) | 2005-10-27 | — | — | US | disclosed |
| US-20050239817-A1 | 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | ALTANA PHARMA AG (DE) | 2005-10-27 | — | — | US | disclosed |
| EP-1539164-A1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1536798-A1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004019944-A1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004019945-A1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239817-A1 | 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4A 1/4885PDE4C 6/4885 |
| US-20080319067-A1 | 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4A 1/4885PDE4C 6/4885 |
| US-20050239818-A1 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4A 1/4885PDE4C 6/4885 |
| US-20090170892-A1 | 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4A 1/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.